Critical Issues for the Translation of Cardioprotection

Critical Issues for the Translation of Cardioprotection

Gerd Heusch

Lack of robust preclinical data, lack of phase II dosing and timing studies, and too loose inclusion criteria in clinical trials contribute to poor translation. Adapted from Rossello and Yellon6 with permission of the publisher. Copyright ©2016, American Heart Association, Inc. Authorization for this adaptation has been obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation. TIMI indicates thrombolysis in myocardial infarction. [Powerpoint File]

Comments are Disabled